Halberd Corporation, in collaboration with Athena Telemedicine Partners, reports positive clinical results for its patent-pending LDX compound in treating dialysis-related neuropathy and itching. The company is initiating a 100-patient study focused on kidney disease and will conduct a 90-day trial for clinicians treating dialysis patients. This builds upon Halberd’s previous research into LDX for managing addiction, inflammation, neurological disorders, and pain.
This development is important because it addresses a significant unmet need in the substantial dialysis patient population. Millions globally suffer from kidney disease and its associated complications, including neuropathy and pruritis, which severely impact quality of life. A successful treatment could significantly improve patient outcomes and open a substantial market opportunity given the growth projections for the dialysis market. Additionally, the positive case report demonstrating LDX’s effectiveness in alleviating these symptoms despite previous treatment failures offers hope for those who have not found relief through existing therapies.
The 100-patient study, supported by Athena GTX’s WatchDawg™ wearable monitoring technology and Verizon’s cloud-based data acquisition, will evaluate LDX’s safety and efficacy. The study will utilize a titrated dose response protocol incorporating low-dose naltrexone, methocarbamol, and natural cinnamon. This data-driven approach will provide objective measures of symptom relief for both patients and healthcare providers. The company also plans a future study on LDX for PTSD, alcohol use disorder, and suicidal ideation.
This positive clinical data and the initiation of larger studies signify a potentially crucial step in addressing the debilitating side effects of dialysis. The results of the planned trials could pave the way for broader application of LDX and potentially offer a new therapeutic avenue for patients suffering from kidney disease and its associated complications. This progress could significantly impact the dialysis treatment landscape and improve the lives of millions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
